Search Results 81-90 of 255 for anti-TNF drugs

  1. A Study to Evaluate the Safety and Effectiveness of Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients with Crohn's Disease - Mayo Clinic

    By condition, treatment or drug name. Search ... TNF-α antagonist or vedolizumab or ustekinumab ... Anti-integrin: at least 14 weeks treatment of the ...

  2. Sulfasalazine (oral route) - Side effects & dosage - Mayo Clinic

    ... drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the ...

  3. Publications - Afsaneh Alavi, M.D. - Mayo Clinic

    Therapeutic drug monitoring in hidradenitis suppurativa patients on adalimumab: A retrospective cohort. J Am Acad Dermatol. 2025 Aug; 93 (2):516-518 Epub ...

  4. Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis - Mayo Clinic

    Drugs & Supplements A-Z · Health Books · Healthy Living Program · Mayo Clinic ... anti-TNF agents, and rituximab). Subjects with an MMT-8 score ≤ 66 (see ...

  5. Stem Cell Coated Fistula Plug in Patients With Crohn's RVF - Mayo Clinic

    ... therapy; Concurrent therapies with corticosteroids, 5-ASA drugs, thiopurines, MTX, antibiotics, and anti-TNF therapy are permitted. All patients should have ...

  6. Publications - Laura E. Raffals, M.D. - Mayo Clinic

    A Prospective Comparison of Ustekinumab and Anti-TNF Therapy in the Treatment of Crohn's-like Disease of the Pouch. Am J Gastroenterol. 2025 Jun 25 Epub ...

  7. Safety and Immune Response of the COVID 19 Vaccine in Patients with Inflammatory Bowel Disease - Mayo Clinic

    ustekinumab mono or combination therapy;; patients on mesalamine or no therapy. Group B (Low vaccine responders):. Anti-TNF monotherapy;; anti-TNF combination ...

  8. A Phase 3 Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Study of SHP647 as Induction Therapy in Subjects With Moderate to Severe Ulcerative Colitis (FIGARO UC 302) - Mayo Clinic

    Drugs & Supplements A-Z · Health Books · Healthy Living Program · Mayo ... Subjects have received anti-TNF treatment within 60 days before baseline (Visit 2).

  9. Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD) - Mayo Clinic

    Demonstrated intolerance or inadequate response to one or more anti-tumor necrosis factor (TNF) therapies. Exclusion Criteria: Current diagnosis of ...

  10. Statins for the Treatment of NASH - Mayo Clinic

    Immune modulatory agents including systemic steroids, methotrexate, anti-TNF-? therapies (infliximab, adalimumab, etanercept) or anti-integrin therapy